首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   18901篇
  免费   1388篇
  国内免费   334篇
耳鼻咽喉   104篇
儿科学   368篇
妇产科学   289篇
基础医学   2453篇
口腔科学   272篇
临床医学   2486篇
内科学   3835篇
皮肤病学   353篇
神经病学   946篇
特种医学   391篇
外国民族医学   1篇
外科学   1707篇
综合类   1365篇
一般理论   47篇
预防医学   2808篇
眼科学   247篇
药学   1324篇
  17篇
中国医学   528篇
肿瘤学   1082篇
  2024年   9篇
  2023年   2099篇
  2022年   2819篇
  2021年   5282篇
  2020年   4465篇
  2019年   242篇
  2018年   220篇
  2017年   189篇
  2016年   215篇
  2015年   213篇
  2014年   380篇
  2013年   393篇
  2012年   306篇
  2011年   388篇
  2010年   340篇
  2009年   321篇
  2008年   305篇
  2007年   319篇
  2006年   307篇
  2005年   241篇
  2004年   253篇
  2003年   221篇
  2002年   145篇
  2001年   129篇
  2000年   105篇
  1999年   82篇
  1998年   68篇
  1997年   54篇
  1996年   61篇
  1995年   43篇
  1994年   29篇
  1993年   39篇
  1992年   27篇
  1991年   29篇
  1990年   22篇
  1989年   13篇
  1988年   11篇
  1987年   8篇
  1985年   36篇
  1984年   37篇
  1983年   23篇
  1982年   23篇
  1981年   23篇
  1980年   16篇
  1979年   13篇
  1977年   10篇
  1976年   5篇
  1975年   10篇
  1974年   6篇
  1973年   18篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
目的调查上海市2022年3月以来新一波新型冠状病毒肺炎(COVID-19)疫情期间方舱医院新冠肺炎患者心理健康状况,并分析影响因素,为开展针对性的心理干预和治疗提供科学依据。方法于2022年4月6日—5月11日,采用横断面研究、方便抽样法,应用微信小程序“同心守沪”对上海市3所方舱医院新冠肺炎患者采用突发性公共卫生事件心理问卷,调查心理健康状况,并初步分析影响因素。结果共268例患者完成问卷调查,心理症状检出者261例(97.4%),其中抑郁、神经衰弱、恐惧、强迫-焦虑、疑病症状检出率分别为80.6%、69.8%、89.6%、75.4%、41%。心理健康总评分影响因素有年龄(P=0.008)、躯体疾病(P=0.03)、既往是否有精神心理问题(P<0.001)、疫情对心身的影响程度(P<0.001);抑郁评分(P=0.019)和神经衰弱评分(P=0.021)还受教育程度影响;神经衰弱评分还受性别影响(P=0.024);疑病评分还受新冠肺炎认知程度影响(P=0.007)。结论上海市方舱医院集中隔离治疗点内患者恐惧、抑郁、强迫-焦虑症状多见,心理异常症状严重程度以轻、中度为主。随年龄越小、受教育程度越高、女性患者、有躯体疾病、既往存在精神心理问题、对新冠肺炎认知程度低、疫情对心身影响程度越大,心理症状总分越高,症状越严重。  相似文献   
3.
[摘要] 目的 探讨上海某方舱医院新型冠状病毒奥密克戎变异株感染者的发病情况及流行病学特征。方法 以2022年4月9日—5月5日上海国家会展中心方舱医院收治的新型冠状病毒奥密克戎变异株感染者为研究对象,对感染者年龄、性别、地区、疫苗接种等疫情数据进行流行病学特征分析。结果 122 151例新型冠状病毒感染者均为奥密克戎变异株BA.2或BA.2.2亚型感染,其流行病学特征结果显示:患者男女比例为1.51:1;平均年龄为(44.91±15.38)岁;0~17岁、18~30岁、31~60岁和≥61岁感染者分别占4.74%、20.80%、62.52%和11.94%;无症状感染者占80.80%,轻型患者占19.20%;平均住院时间为(7.00±2.77)d;未接种和完成1、2和3次疫苗接种的感染者分别占20.30%、3.18%、31.30%和45.22%,其中≥61岁且完成3次疫苗接种的感染者仅占10.10%。结论 各个年龄段人群对于新型冠状病毒奥密克戎变异株普遍易感。无症状感染者是本次疫情的主体人群,临床症状不典型,早期隐匿传播,积极加强核酸检测是早期发现疫情的必要手段。  相似文献   
4.
5.
The coronavirus disease 2019 (COVID-19) pandemic continues to be a global problem with over 438 million cases reported so far. Although it mostly affects the respiratory system, the involvement of extrapulmonary organs, including the liver, is not uncommon. Since the beginning of the pandemic, metabolic com-orbidities, such as obesity, diabetes, hypertension, and dyslipidemia, have been identified as poor prognostic indicators. Subsequent metabolic and lipidomic studies have identified several metabolic dysfunctions in patients with COVID-19. The metabolic alterations appear to be linked to the course of the disease and inflammatory reaction in the body. The liver is an important organ with high metabolic activity, and a significant proportion of COVID-19 patients have metabolic comorbidities; thus, this factor could play a key role in orchestrating systemic metabolic changes during infection. Evidence suggests that metabolic dysregulation in COVID-19 has both short- and long-term metabolic implications. Furthermore, COVID-19 has adverse associations with metabolic-associated fatty liver disease. Due to the ensuing effects on the renin-angiotensin-aldosterone system and ammonia metabolism, COVID-19 can have significant implications in patients with advanced chronic liver disease. A thorough understanding of COVID-19-associated metabolic dysfunction could lead to the identification of important plasma biomarkers and novel treatment targets. In this review, we discuss the current understanding of metabolic dysfunction in COVID-19, focusing on the liver and exploring the underlying mechanistic pathogenesis and clinical implications.  相似文献   
6.
Numerous risk variables, including age, medical co-morbidities, and deranged inflammatory response, lead to higher mortality in a senior population with coronavirus disease 2019. C-reactive protein (CRP), an acute phase inflammatory protein secreted by the liver, was tested in the elderly, showing a diagnostic and prognostic role. However, recent research has shed light on new applications for CRP in geriatrics. It was used as a follow-up marker and as a therapeutic target. Early and accurate identification of patients' risks may mitigate the devastation of the invading virus in older cases and permit the implementation of a quick treatment plan for those most likely to deteriorate.  相似文献   
7.
Information regarding the impact of the coronavirus disease 2019 (COVID-19) pandemic on cervical cancer in mainland China is lacking. We explored its impact on the hospital attendance of patients with primary cervical cancer. We included 1918 patients with primary cervical cancer who initially attended Harbin Medical University Cancer Hospital between January 23, 2019, and January 23, 2021. Attendance decreased by 31%, from 1135 in 2019 to 783 in 2020, mainly from January to June (𝜒2 = 73.362, P < .001). The percentage of patients detected by screening decreased from 12.1% in January-June 2019 to 5.8% in January-June 2020 (𝜒2 = 7.187, P = .007). Patients with stage I accounted for 28.4% in 2020 significantly lower than 36.6% in 2019 (𝜒2 = 14.085, P < .001), and patients with stage III accounted for 27.1% in 2020 significantly higher than 20.5% in 2019 (𝜒2 = 11.145, P < .001). Waiting time for treatment was extended from 8 days (median) in January-June and July-December 2019 to 16 days in January-June (𝜒2 = 74.674, P < .001) and 12 days in July-December 2020 (𝜒2 = 37.916, P < .001). Of the 179 patients who delayed treatment, 164 (91.6%) were for the reasons of the healthcare providers. Compared to 2019, the number of patients in Harbin or non-Harbin in Heilongjiang Province and outside the province decreased, and cross-regional medical treatment has been hindered. The COVID-19 pandemic has negatively impacted cervical cancer patient attendance at the initial phase. These results are solid evidence that a strategy and mechanism for the effective attendance of cervical cancer patients in response to public health emergencies is urgently needed.  相似文献   
8.
Previous studies on the immunogenicity of SARS-CoV-2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim of our study is to evaluate the immunogenicity of two doses of mRNA vaccines in solid cancer patients with or without a previous exposure to the virus. This is a single-institution, prospective, nonrandomized study. Patients in active treatment and a control cohort of healthy people received two doses of BNT162b2 (Comirnaty, BioNTech/Pfizer, The United States) or mRNA-1273 (Spikevax, Moderna). Vaccine was administered before starting anticancer therapy or on the first day of the treatment cycle. SARS-CoV-2 antibody levels against S1, RBD (to evaluate vaccine response) and N proteins (to evaluate previous infection) were measured in plasma before the first dose and 30 days after the second one. From January to June 2021, 195 consecutive cancer patients and 20 healthy controls were enrolled. Thirty-one cancer patients had a previous exposure to SARS-CoV-2. Cancer patients previously exposed to the virus had significantly higher median levels of anti-S1 and anti-RBD IgG, compared to healthy controls (P = .0349) and to cancer patients without a previous infection (P < .001). Vaccine type (anti-S1: P < .0001; anti-RBD: P = .0045), comorbidities (anti-S1: P = .0274; anti-RBD: P = .0048) and the use of G-CSF (anti-S1: P = .0151) negatively affected the antibody response. Conversely, previous exposure to SARS-CoV-2 significantly enhanced the response to vaccination (anti-S1: P < .0001; anti-RBD: P = .0026). Vaccine immunogenicity in cancer patients with a previous exposure to SARS-CoV-2 seems comparable to that of healthy subjects. On the other hand, clinical variables of immune frailty negatively affect humoral immune response to vaccination.  相似文献   
9.
AimThis review aims to summarize and discuss some of the most relevant clinical trials in epidemiology, diagnostics, and treatment of hypertension published in 2020 and 2021.Data synthesisThe trials included in this review are related to hypertension onset age and risk for future cardiovascular disease, reliability of different blood pressure monitoring methods, role of exercise-induced hypertension, treatment of hypertension in patients with SARS-CoV-2 infection, management of hypertension high-risk patient groups, e.g., in the elderly (≥80 years) and patients with atrial fibrillation, and the interplay between nutrition and hypertension, as well as recent insights into renal denervation for treatment of hypertension.ConclusionsHypertension onset age, nighttime blood pressure levels and a riser pattern are relevant for the prognosis of future cardiovascular diseases. The risk of coronary heart disease appears to increase linearly with increasing exercise systolic blood pressure. Renin-angiotensin system blockers are not associated with an increased risk for a severe course of COVID-19. In elderly patients, a risk-benefit assessment of intensified blood pressure control should be individually evaluated. A J-shaped association between cardiovascular disease and achieved blood pressure could also be demonstrated in patients with atrial fibrillation on anticoagulation. Salt restriction and lifestyle modification remain effective options in treating hypertensive patients at low cardiovascular risk. Sodium glucose co-transporter 2 inhibitors and Glucagon-like peptide-1 receptor agonists show BP-lowering effects. Renal denervation should be considered as an additional or alternative treatment option in selected patients with uncontrolled hypertension.  相似文献   
10.
韩彬  樊华伟  曹萌 《中国药事》2022,36(1):16-24
目的:探讨提升商业化mRNA疫苗生产质量水平以降低风险、提升获益,确保疫苗生产过程符合法规要求,并推进监管领域相关标准、技术指南的完善。方法:通过分析mRNA疫苗生产技术特点,梳理mRNA疫苗产品各个生产环节中的质量风险点,综述相关领域研究进展,并探讨mRNA疫苗生产现场监管检查的一些要点。结果与结论:mRNA疫苗生产一般包括转录模板制备、原液生产、制剂生产和灌装等步骤,其中产生抗原作用的mRNA分子一般采用体外表达系统,制剂生产一般采用脂质纳米颗粒(LNP)技术。基于mRNA疫苗产品的固有风险、特定生产要求和工艺特征,明确应关注DNA模板的制备、场地设施条件、对RNA酶的控制、工艺杂质控制能力及质量保证程度、LNP生产稳健性、储运低温与防震能力、委托检验管理等方面的现场情况。建议尽快制定相关标准、指南细则,以包容审慎的态度在保证质量的前提下推进mRNA产业发展,提升疫苗生产全链条质量保证水平。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号